No Authorization For OTC Monograph Reform And User Fees, But Webinar Goes On
This article was originally published in The Rose Sheet
FDA’s Aug. 23 webinar will update industry stakeholders on progress to modernize its OTC monograph program, but without user fee legislation, new performance goals will not take effect; stakeholders hold out hope a standalone OTC user fee bill could still progress in Congress.
You may also be interested in...
Members of the House Health Subcommittee suggest their support for potential OTC monograph reform legislation depends on including provisions that would add substantial details to FDA's oversight of cosmetics manufacturers and a related user fee program.
House Health Subcommittee's “Modernizing FDA’s Regulation of Over-the-Counter Drugs” hearing Sept. 13 will "examine draft legislation to establish" a user fee program to support FDA's work on evaluating proposals for additions or changes to its nonprescription drug monographs.
The 2017 user fee reauthorization bill contains provisions that should be significantly easier for the agency to implement compared with the 2012 measure. Senate clears clean bill for president's review.